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DOI: 10.1039/b822015hPhytochemicals occluded in tea have been extensively used as dietary supplements and as natural
pharmaceuticals in the treatment of various diseases including human cancer. Results on the reduction
capabilities of phytochemicals present in tea to reduce gold salts to the corresponding gold
nanoparticles are presented in this paper. The phytochemicals present in tea serve a dual role as
effective reducing agents to reduce gold and also as stabilizers to provide a robust coating on the gold
nanoparticles in a single step. The tea-generated gold nanoparticles (T-AuNPs), have demonstrated
remarkable in vitro stability in various buffers including saline, histidine, HSA, and cysteine solutions.
T-AuNPs with phytochemical coatings have shown significant affinity toward prostate (PC-3) and
breast (MCF-7) cancer cells. Results on the cellular internalization of T-AuNPs through endocytosis
into the PC-3 and MCF-7 cells are presented. The generation of T-AuNPs follows all principles of green
chemistry and T-AuNPs have been found to be non toxic as assessed through MTT assays. No ‘man
made’ chemicals, other than gold salts, are used in this truly biogenic, green nanotechnological process
thus paving the way for excellent opportunities for their application in molecular imaging and therapy.Introduction
Beginning in the bygone era of 2700 BC, when the second emperor
of China, Shen Nung, discovered tea, this beverage has become
the most popular, soothing and delicious drink in human history.1
Throughout history and transitioning into the 21st century, tea
drinking has been directly attributed to a plethora of health
benefits.2,3 Several studies suggest that consumption of tea results
in lowering the risk of stroke,4 reducing the risk of cancer,5–9
lowering blood pressure,9 enhancing immune function,10 and
preventing dental cavities11 and gingivitis.3,12–24 The growing
evidence towards the health benefits of tea has resulted in exten-
sive studies to unravel the scientific basis of the healing and curing
power of tea.3,4 A well-accepted scientific consensus emanating
from several scientific investigations is that tea contains high
levels of antioxidant polyphenols, including flavonoids, and
catechins, all of which scavenge the dangerous free radicals in the
body and thus, prevent the progress of various diseases.25–34
Polyphenolic flavonoids in tea (Fig. 1), of which epigallocatechin
gallate (EGCG) is the second major constituent, have anticarci-
nogenic activity in vitro, which may support the results of epide-
miological research on the correlation between drinking tea and
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2912 | J. Mater. Chem., 2009, 19, 2912–2920superoxide anion radicals (O2c), hydrogen peroxide (H2O2),
hydroxyl radicals (HOc), peroxyl radicals, singlet oxygen, and
peroxynitrite.25–34 The one-electron reduction potential of EGCGFig. 1 Composition of various phytochemicals in black tea leaves.
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under standard conditions is 550 mV, a value lower than that of
glutathione (920 mV) and comparable to that of a-tocopherol
(480 mV).29 While the tremendous health benefits of the ‘chemical
cocktails’ occluded within tea (Fig. 1) are beyond doubt, the
actual applications of the chemical reduction power of the myriad
of chemicals present in tea is still in its infancy. We hypothesize
that, the synergistic reduction potentials of polyphenols including
flavonoids, catechins and various phytochemicals present in tea,
will reduce gold salts to produce gold nanoparticles for potential
applications in medicine and technology. Validation of this
hypothesis will have long lasting positive repercussions in the
chemical, electronic materials, health and hygiene industries,
because such an approach will provide an ideal platform for the
production of gold nanoparticles under 100% green chemistry
conditions without the intervention of any ‘man-made’ chemicals
following all principles of green chemistry. Gold nanoparticles are
currently used in a wide spectrum of applications ranging from
chemical catalysis to electronic materials design.35–46 Gold nano-
particles have also found considerable prominence in the devel-
opment of biological sensors and in the design and development
of diagnostic and therapeutic nanomedicine products.13,35–49 As
the nanorevolution, in the realms of medical and technological
applications, unfolds, it is imperative to develop environmentally
benign and biologically friendly green chemical processes.23,50–85
Naturally grown plants and various plant species which occlude
phytochemicals may serve as long lasting and environmentally
benign reservoirs for the production of a myriad of metallic
nanoparticles. We, herein, present an unprecedented synthetic
approach that involves the production of well-defined gold
nanoparticles by the simple mixing of an aqueous solution of
sodium tetrachloroaurate (NaAuCl4) with an aqueous solution of
Darjeeling tea leaves. Production of gold nanoparticles (T-
AuNPs 1–4) in this phytochemically-mediated process leads to
completion at 25 C within 30 minutes. Gold nanoparticles
generated through this process do not agglomerate suggesting
that the combination of thearubigins, theaflavins, catechins and
various phytochemicals present in tea also serve as excellent
stabilizers on nanoparticles and thus, provide robust shielding
from agglomeration. Cellular uptake and cytotoxic studies of T-
AuNPs were examined in Human Prostate (PC-3) and Breast
cancer cells (MCF-7). The phytochemically coated T-AuNPs
showed excellent affinity toward receptors on prostate and breast
tumor cells. The details of the synergistic advantages of using tea
in this green nanotechnological process for a dual role involving
gold nanoparticle production and stabilization in a single process
are discussed.Materials and methods
Chemicals
All chemicals and tea precursors used in the synthesis of gold
nanoparticles (AuNPs) were procured from standard vendors:
NaAuCl4 (Alfa-Aesar) and tea from organic grocery sources.
Transmission electron microscope (TEM) images were obtained
on a JEOL 1400 transmission electron microscope (TEM), JEOL
Ltd, Tokyo, Japan. TEM samples were prepared by placing 5 mL
of gold nanoparticle solution on a 300 mesh carbon-coated
copper grid and allowing the solution to stand for five minutes;This journal is ª The Royal Society of Chemistry 2009excess solution was removed carefully and the grid was allowed
to dry for an additional five minutes. The average size and size
distribution of the gold nanoparticles synthesized were deter-
mined by the processing of the TEM image using image pro-
cessing software such as Adobe Photoshop (with Fovea plug-
ins). The absorption measurements were done using Varian Cary
50 UV-Vis spectrophotometers with 1 mL of gold nanoparticle
solution in disposable cuvettes of 10 mm path length.
Tea-initiated and -stabilized gold nanoparticles (T-AuNP-1)
To a 10 mL vial was added 6 mL of doubly ionized water (DI),
followed by the addition of 100 mg of tea leaves (Darjeeling tea).
The reaction mixture was stirred continuously at 25 C for 15
min. To the stirring mixture was added 100 mL of 0.1 M NaAuCl4
solution (in DI water). The color of the mixture turned purple-
red from pale yellow within 5 minutes of the addition, indicating
the formation of gold nanoparticles. The reaction mixture was
stirred for an additional 15 minutes. The gold nanoparticles thus
formed were separated from residual tea leaves immediately
using a 5 micron filter and were characterized by UV-Vis
absorption spectroscopy and TEM analysis.
Tea-initiated and gum arabic-stabilized gold nanoparticles
(T-AuNP-2)
To a 10 mL vial was added 0.012 g of gum arabic, 6 mL of doubly
ionized water (DI), followed by the addition of 100 mg of tea
leaves (Darjeeling tea). The reaction mixture was stirred
continuously at 25 C for 15 min. To the stirring mixture was
added 100 mL of 0.1 M NaAuCl4 solution (in DI water). The
color of the mixture turned purple-red from pale yellow within 10
minutes indicating the formation of gold nanoparticles. The
reaction mixture was stirred for an additional 15 minutes. The
gold nanoparticles thus formed were separated from residual tea
leaves immediately using a 5 micron filter and were characterized
by UV-Vis absorption spectroscopy and TEM.
Tea-initiated and -stabilized gold nanoparticles at 40 C
(T-AuNP-3)
To a 10 mL vial was added 6 mL of doubly ionized water (DI),
followed by the addition of 100 mg of tea leaves (Darjeeling tea).
The reaction mixture was stirred continuously at elevated
temperature (40 C) for 5 min. To the warm stirring mixture
was added 100 mL of 0.1 M NaAuCl4 solution (in DI water). The
color of the mixture turned purple-red from pale yellow instantly
indicating the formation of gold nanoparticles. The reaction
mixture was stirred for an additional 5 minutes. The gold
nanoparticles in DI water were separated from residual tea leaves
immediately using a 5 micron filter and were characterized by
UV-absorption spectroscopy and TEM analysis.
Tea-initiated and gum arabic-stabilized gold nanoparticles at
40 C (T-AuNP-4)
To a 10 mL vial was added 0.012 g of gum arabic, 6 mL of doubly
ionized water (DI), followed by the addition of 100 mg of tea
leaves (Darjeeling tea). The reaction mixture was stirred
continuously at elevated temperature ( 40 C) for 5 min. To theJ. Mater. Chem., 2009, 19, 2912–2920 | 2913
Scheme 1 Synthesis of T-AuNPs from black Darjeeling tea leaves.warm stirring mixture was added 100 mL of 0.1 M NaAuCl4
solution (in DI water). The color of the mixture turned purple-
red from pale yellow in about 5–10 min indicating the formation
of gold nanoparticles. The reaction mixture was stirred for 5
more minutes. The gold nanoparticles in DI water were sepa-
rated immediately using a 5 micron filter. The tea/gum arabic
stabilized gold nanoparticles (T-AuNP-4) were characterized by
UV-absorption spectroscopy and TEM analysis.
In vitro stability studies of gold nanoparticles synthesized using
tea leaves
In vitro stabilities of the four different tea-mediated gold nano-
particles (T-AuNPs, 1–4) were tested in the presence of NaCl,
cysteine, histidine, HSA and BSA solutions. Typically, 1 mL of
gold nanoparticle solution was added to glass vials containing 0.5
mL of 5% NaCl, 0.5% cysteine, 0.2 M histidine, 0.5% HSA and
0.5% BSA solutions respectively and incubated for 30 min. The
stability and the identity of gold nanoparticles (T-AuNPs 1–4)
were measured by recording UV absorbance after 30 min. The
plasmon resonance band at 535 nm confirmed the retention of
nanoparticulates in all the above mixtures. TEM measurements
inferred the retention of the nanoparticulate compositions in all
the above four different gold nanoconstructs, signifying the
robust nature of these nanoparticles under in vitro conditions.
Cell culture
Minimum essential medium (MEM with nonessential amino
acids, powdered), HEPES, bovine insulin, streptomycin sulfate
and penicillin-G, were obtained from Sigma Chemical Company
(St. Louis, MO); all were ‘‘cell culture tested’’ when available.
Bovine calf serum, phenol red (sodium salt), and lyophilized
trypsin were obtained from Gibco BRL (Grand Island, NY).
MCF-7 breast and PC-3 prostate cancer cells were obtained from
ATCC. MCF-7 cells were maintained in MEM with nonessential
amino acids, 10 pg ml1 phenol red, 10 mM HEPES, 6 ng ml1
insulin, 100 units ml1 penicillin, 100 pg ml1 streptomycin, and
5% charcoal-stripped calf serum (maintenance medium). PC-3
cells were maintained in RPMI medium supplemented with 4.5 g
L1 D-glucose, 25 mM HEPES, 0.11 g L1 sodium pyruvate, 1.5 g
L1 sodium bicarbonate, 2 mM L-glutamine and 10% FBS and
antibiotics.
Cell internalization studies
About 16,000 cells were plated into each well in a 6 well plate and
this plate was incubated at 37 C for 24 h to allow the cells to
recover. After the cells were recovered, the medium from each
well was aspirated and fresh growth medium was added (about 4
mL per well). Cells were allowed to grow for 3 days and the
media was changed every alternate day. On the 5th day, 25
micromolar T-AuNP-1 (Au atoms) solution was added to each
well. After adding the sample, the plate was incubated for 4 h at
37 C. Medium was aspirated from each well after 4 h and the cell
layer was rinsed with CMFH–EDTA (Calcium-Magnesium-
Free-Hark’s + HEPES–EDTA) solution to remove all traces of
serum. About 1 mL of trypsin–EDTA solution was added to
each well and the cells were observed under an inverted micro-
scope until the cell layer was dispersed. 4.0 mL of complete2914 | J. Mater. Chem., 2009, 19, 2912–2920growth medium was added to each well and the cells were aspi-
rated by gently pipetting. The cell suspension was transferred
into a centrifuge tube and centrifuged at approximately 125  g
for 5 to 10 minutes. The cells were washed thoroughly with
chilled PBS, pelleted by centrifugation and fixed with 0.1 M Na-
cacodylate buffer containing 2% glutaraldehyde and 2% para-
formaldehyde. The pellets were post fixed with 1% osmium
tetraoxide, dehydrated and embedded in Epon/Spurr’s resin and
80 nm sections were collected and placed on TEM grids followed
by sequential counter staining with uranyl acetate and lead
citrate. TEM grids were observed under TEM (JEOL 1400) and
images were recorded at different magnifications.Cytotoxicity evaluations
An MTT Cell Proliferation Assay kit was obtained from ATCC.
For the cytotoxicity evaluation of these nanoparticles, MTT
assay was done as described by the supplier. Briefly, 1  105 ml1
cells at the exponential growth phase were placed in a flat-
bottomed 96-well polystyrene-coated plate and were incubated
for 24 h in a CO2 incubator at 5% CO2 and 37
C. A series of
dilutions of 10, 25, 50, 100, and 150 mM of T-AuNP-1 were made
in the medium. Each concentration was added to the plate in
quadruplet. After 24 h of incubation, 10 ml/well MTT (stock
solution 5 mg ml1 PBS) was added for 6 h and the formazan
crystals formed were dissolved in 100 ml detergent. The plates
were read in a microplate reader (Dynastic MR 5000, USA)
operating at 570 nm. Wells with complete medium, nano-
particles, and MTT, but without cells were used as blanks. All
experiments were performed three times in quadruplet, and the
average of all the experiments has been shown as a cell-viability
percentage in comparison with the control experiment, while
gold untreated controls were considered as 100% viable.Results and discussion
As part of our ongoing efforts toward the design and develop-
ment of biocompatible gold nanoparticles for subsequent use in
medical applications, we have initiated studies on the direct
intervention of phytochemicals for the production of gold
nanoparticles. Our new process for the production of gold
nanoparticles uses the direct interaction of sodium tetra-
chloaurate with black Darjeeling tea leaves in aqueous media
(Scheme 1) without the intervention of any external man-made
chemicals. Therefore, this reaction pathway satisfies all the
conditions of a 100% green chemical process.86–88 TheThis journal is ª The Royal Society of Chemistry 2009
composition of various phytochemicals in black tea is outlined in
Fig. 1. Gold nanoparticles produced by this process did not
require any external chemicals for the stabilization of the nano-
particulate matrix. Phytochemicals present in tea (Fig. 1) are
presumably responsible for the creation of a robust coating on
gold nanoparticles and thus, rendering the nanoparticles stable
against agglomeration.
Absorption measurements indicated that the plasmon reso-
nance wavelength, lmax of T-AuNPs is 535 nm. The sizes of
T-AuNPs are in the range of 15–42 nm as measured by TEM
techniques (Fig. 2). The phenolics and other phytochemicals
within tea (Fig. 1) not only result in effective reduction of gold
salts to nanoparticles but their chemical framework is also
effective at wrapping around the gold nanoparticles to provide
excellent robustness against agglomeration. The current
discovery of the unique chemical power of phytochemicals
in tea in initiating nanoparticle formation is of paramount
importance in the context of the production of gold nano-
particles for medical and technological applications under non-
toxic conditions.23,55,57–61 One of the paramount prerequisites of
utilizing AuNPs for in vivo imaging and therapy applications is
that the nanoparticles be produced and stabilized in biologically
benign media.23,55,57–61,49,89 With the currently available methods
of producing AuNPs, it is often necessary to remove unreacted
toxic chemicals and byproducts. Typical known methods of
making gold nanoparticles utilize harsh conditions, such as the
application of sodium borohydride to reduce AuCl4
.90,91
Although such processes lead to the efficient production of gold
nanoparticles, the presence of sodium borohydride, even in
trace amounts, is unsuitable for use in biomedical applications
of gold nanoparticles. The high reduction capabilities of sodium
borohydride result in reduction of biogenic chemical function-
alities present on peptide backbones, thus either reducing or
eliminating the biospecificity of biomolecules. Normally, thiol-
containing organic compounds are employed to stabilize
AuNPs against agglomeration.91 Thiol–gold interaction is
strong and makes gold nanoparticles highly stable. Therefore,
such AuNPs once stabilized by thiols cannot be further conju-
gated to useful drug moieties including peptides, proteins and
various biochemical vectors that are normally used to target
diagnostic and therapeutic gold nanoparticles onto tumors and
various disease sites in the body. This means that the thiol-
stabilized AuNPs will have limited applicability in the devel-
opment of AuNP-labeled biomolecules for use in the design of
target-specific nanoscale imaging or therapeutic agents. Other
methods that have been described in the literature utilize
a cocktail of chemicals in their production processes. Such
techniques are not environmentally friendly and have many
drawbacks that impede the efficient utilization of AuNPs in
biomedical applications.Fig. 2 (A) UV-visible absorption spectra, (B) TEM images and (C) size
distribution histograms of T-AuNPs.Nanoparticle size characterization and size distribution
Physicochemical properties, such as size, charge, and
morphology of gold nanoparticles generated using aqueous
solutions of tea leaves, were determined by three independent
techniques viz. transmission electron microscopy (TEM), differ-
ential centrifugal sedimentation (DCS, Disc Centrifuge, CPS
Instruments), and dynamic light scattering (DLS). TEM andThis journal is ª The Royal Society of Chemistry 2009DCS were used to determine the core size of gold nanoparticles
and DLS was used to evaluate the size of tea phytochemical-
coated gold.J. Mater. Chem., 2009, 19, 2912–2920 | 2915
Table 1 Physicochemical data parameters of T-AuNPs
Sample TEM DLSa CPS Zeta potential/mV
T-AuNP-1 35  7 105  1 28  1 32  1
T-AuNP-2 30  3 165  1 25  1 25  1
a Hydrodynamic diameter.
Fig. 3 UV-Vis absorption spectrum of gold nanoparticles generated
using (A) commercially available phytochemicals from tea, (B)
commercially available phytochemicals from tea and gum arabic. T-
AuNP-5 to T-AuNP-11 correspond to the gold nanoparticles generated
using thiaflavins, epicatechin gallate, catechin, catechin gallate, epi-
catechin, epigallocatechin and EGCG respectively. TEM images of gold
nanoparticles obtained using (C) catechin only (D) epigallocatechin
gallate only.Size and morphology. TEM measurements on T-AuNPs
synthesized using tea leaves show that the particles are spherical
in shape within the size range of 15–45 nm (Table 1). Size
distribution analysis of T-AuNPs confirms that particles are
well dispersed (Fig. 2 and Table 1). DCS technique measures
the sizes of nanoparticles by determining the time required for
nanoparticles to traverse a sucrose density gradient created in
a disc centrifuge. Both the techniques, TEM and DCS, provide
sizes of metallic-gold cores. Gold nanoparticulate sizes
measured by TEM and DCS, are in good agreement and are in
the range of 15–45 nm (Fig. 2 and Table 1). Dynamic light
scattering method was employed to calculate the sizes of gold
nanoparticles coated with phytochemicals (hydrodynamic
radius). The tea phytochemical coatings on gold nanoparticles
are expected to cause substantial changes in the hydrodynamic
radii of T-AuNPs. The hydrodynamic diameters of T-AuNP-1
and T-AuNP-2 as determined from DLS measurements gave
values of 105  1 and 165  1 respectively, suggesting that tea
phytochemicals (catechins, theaflavins and thearibigins) are
capped on gold nanoparticles. The measurement of charge on
nanoparticles, zeta potential (z), provides crucial information
on the stability of nanoparticle dispersion. The magnitude of
the measured zeta potential is an indication of the repulsive
forces that are present and can be used to predict the long-term
stability of the nanoparticulate dispersion. The stability of
nanoparticulate dispersion depends upon the balance of the
repulsive and attractive forces that exist between nanoparticles
as they approach one another. If all the particles have a mutual
repulsion then the dispersion will remain stable. However,
little or no repulsion between particles, lead to aggregation.
The negative zeta potential of 32  1 and 25  1 for
T-AuNP-1 and T-AuNP-2 indicates that the particles repel each
other and there is no tendency for the particles to aggregate
(Table 1 and Fig. 2).
Role of tea phytochemicals
Synthetic conditions have been optimized for the quantitative
large scale conversions of NaAuCl4 to the corresponding AuNPs
using tea leaves. Specific details on the nature and chemical roles
of different phytochemicals in tea leaves responsible for the
production of T-AuNPs are summarized in the following
sections. The main phytochemicals present in black tea leaves
consist of water soluble catechins (catechin, epicatechin, epi-
catechin gallate, epigallocatechin, epigallocatechin gallate etc.,),
theaflavins (theaflavin, theaflavin 3-gallate, theaflavin 30-gallate,
theaflavin 3,30-gallate etc.,) and Thearubigins which are oligo-
mers of catechins of unknown structure. Generation of T-
AuNPS using tea leaves involves aqueous media. Therefore,
water soluble phytochemicals of tea (Fig. 1) may be playing2916 | J. Mater. Chem., 2009, 19, 2912–2920a major role in the overall reduction reactions of NaAuCl4. We
have systematically investigated the roles of catechins and thea-
flavins for the generation and stabilization of AuNPs through
independent experiments.
(i) Role of catechins. In order to understand the critical roles
of the various catechins present in black tea leaves on the overall
reduction of NaAuCl4 to the corresponding gold nanoparticles,
we have performed a series of independent experiments using
directly the commercially available family of catechins which
include: catechin, epicatechin, epicatechin gallate, catechin
gallate, epigallocatechin, and epigallocatechin gallate (see ESI†).
Results of our experiments using commercially available cate-
chins have unambiguously confirmed that catechins are excellent
reducing and stabilizing agents to reduce Au(III) to the corre-
sponding gold nanoparticles. These reactions proceeded to
completion within 30 min. Absorption measurements indicated
that the plasmon resonance wavelength, lmax, for all the T-
AuNPs is 530 nm (Fig. 3). The sizes of the T-AuNPs were
found to be in the 15–42 nm range as measured from the TEM
images. (Fig. 3). The gold nanoaparticles obtained using cate-
chin, and epigallocatechin gallate (EGCG) showed excellent
stability which was confirmed by their in vitro stability studies.
However, gold nanoparticles generated using epigallocatechin
and epicatechin displayed minimum stability as shown byThis journal is ª The Royal Society of Chemistry 2009
characteristic broad plasmon bands (Fig. 3A). Our studies have
unequivocally confirmed that epigallocatechin and epicatechin are
very effective in reducing tetrachloroaurate salt to the corre-
sponding AuNPs. However, these phytochemicals failed to
provide effective coating to shield the nanoparticles from
agglomeration. In order to capitalize on the reduction powers of
epigallocatechin and epicatechin, we have utilized gum arabic (a
glycoprotein) as a naturally available stabilizing agent in our
reactions. Results from these experiments have revealed that all
the catechins (catechin, epicatechin, epicatechin gallate, epi-
gallocatechin, eatechin gallate and epigallocatechin gallate) act
as excellent reducing agents to reduce the Au(III) to the corre-
sponding gold nanoparticles. The nanoparticles thus generated
were coated with gum arabic stabilizing agent and showed
significant stability when challenged with various salts and serum
proteins (Fig. 5). These experiments have unambiguously
confirmed that catechin and epigallocatechin gallate (EGCG)
serve dual roles as reduction and stabilizing agents whereas epi-
gallocatechin and epicatechin, can be used only for the reduction
of gold salts and require gum arabic as an external stabilizing
agent.
(ii) Role of theaflavins. We have also investigated the role of
theaflavins in the generation of gold nanoparticles. Commer-
cially available tea extract (Sigma) which contains >80% of
theaflavins was used in these experiments (see ESI†). Addition
of aqueous solution of NaAuCl4 to aqueous solution of the-
aflavin at 25 C resulted in the formation of purple colored
solutions within 30 minutes. The gold nanoparticles thus
obtained by using theaflavin were characterized by UV-Vis
absorption spectroscopy and TEM. A plasmon resonance
band at 535 nm indicated the formation of gold nano-
particles (Fig. 3). TEM measurements confirmed the size
distribution of gold nanoparticles. Detailed in vitro stabilities
of the gold nanoparticles confirmed that the nanoparticles are
extremely stable under various conditions. These results
convincingly demonstrate the dual reduction and stabilizing
capabilities of mixtures of theaflavins present in tea. The
reservoir of non-toxic phytochemicals in tea (Fig. 1 and Fig. 4)
is pivotal as they serve as a source of non-toxic reducing
agents with capabilities for in vivo administration in situationsFig. 4 Venn diagram showing the possible role of phytochemicals in tea
for the generation and stabilization of gold nanoparticles.
This journal is ª The Royal Society of Chemistry 2009that require the generation of gold nanoparticles under in vivo
conditions.
It is remarkable to note that intervention of a second green
component, in the form of gum arabic (GA), in the above reac-
tions provides additional advantages. The use of GA along with
tea leaves resulted in an increase in the optical density (absor-
bance) in the UV-Vis spectra of reaction mixtures (Fig. 2).51 This
observation demonstrates that GA may be presumably serving as
a biochemical platform to drive such reactions to completion
with the consequent production of well-defined and uniform
spherical gold nanoparticles. We have also investigated the effect
of temperature on the formation of gold nanoparticles using only
tea leaves as well as a combination of tea leaves and GA. Results
of these reactions performed at 40 C have revealed that nano-
particle formation at elevated temperatures results in randomly
distributed spherical gold nanoparticles of sizes varying from 15–
30 nm (Fig. 2).
In vitro stability studies
An issue of critical importance for in vivo molecular imaging
applications is the stability of AuNPs over a reasonable time
period. The stability of T-AuNPs was evaluated by monitoring
the plasmon (lmax) in 0.5% cysteine, 0.2 M histidine, 0.5%
Human Serum Albumin (HSA), 0.5% Bovine Serum Albumin
(BSA) or 5% NaCl solutions over 30 min. We have also inves-
tigated the stability of T-AuNPs at pH 5, 7 and pH 9 phosphate
buffer solutions. The plasmon wavelengths in all the above
formulations show minimal shifts of 1–5 nm. Our results from
these in vitro stability studies have confirmed that the AuNPs are
intact and thus, demonstrate excellent in vitro stability of T-
AuNPs in biological fluids at physiological pH (Fig. 5). For
various biomedical applications which require lower concentra-
tions of AuNPs, it is vitally important that dilutions of AuNP
solutions do not alter their characteristic chemical and photo-
physical properties. We have undertaken a detailed investigation
to ascertain the effect of dilution on the stability of T-AuNP-1. In
order to establish the stability of T-AuNPs under dilution, the
plasmon resonance wavelength (lmax) was monitored after everyFig. 5 In vitro stability studies of T-AuNP-1 and T-AuNP-2: UV-visible
absorption spectra and TEM images.
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successive addition of 0.1 mL of doubly ionized (DI) water to 1
mL of AuNP solutions. The absorption intensity at lmax is found
to be linearly dependent on the concentration of AuNPs, in
accordance with the Beer–Lambert law. It is important to
recognize that lmax of the AuNPs did not change at very dilute
conditions (Fig S1†). These are typical concentrations encoun-
tered when working at cellular levels.
It is conceivable that the cocktail of phytochemicals in tea
along with non-toxic phytochemical gum arabic (Fig. 1) are
acting synergistically in stabilizing gold nanoparticles from any
agglomeration in solution. It is also remarkable that this ‘nano-
compatible’ structural motif of phytochemicals in tea offers
stability to gold nanoparticles in aqueous media for over
a month. These results suggest that the green nanotechnological
process reported herein provides both the production and
stabilization processes under mild conditions without the inter-
vention of any man made harsh chemicals.
Cellular interactions of T-AuNPs
Cellular internalization studies of gold nanoparticle solutions
provide insights into cellular uptake and such information will
enhance the scope of gold nanoparticles in biomedicine. Gold
nanoparticles are currently investigated for their potential
applications as diagnostic/therapeutic agents, therapeutic
delivery vectors, and intracellular imaging agents.92–97 Selective
cell and nuclear targeting of gold nanoparticles will provide new
pathways for the site specific delivery of gold nanoparticles as
diagnostic/therapeutic agents. A number of studies have
demonstrated that phytochemicals in tea have the ability to
penetrate the cell membrane and internalize within the cellular
matrix.98–101 Cancer cells are highly metabolic and porous in
nature and are known to internalize solutes rapidly compared to
normal cells.101–103 Therefore, we hypothesized that tea-derived
phytochemicals, if coated on gold nanoparticles, would show
internalization within cancer cells. We undertook cellular inter-
action and uptake studies via incubation of aliquots of T-AuNP-Fig. 6 TEM images showing endocytosis of T-AuNP-1 in cells.
2918 | J. Mater. Chem., 2009, 19, 2912–29201 with prostate (PC-3) and breast cancer (MCF-7) cells. TEM
images of prostate (PC-3) and breast tumor (MCF-7) cells post
treated with T-AuNP-1 unequivocally validated our hypothesis.
Significant internalization of nanoparticles via endocytosis
within the MCF-7 and PC-3 cells was observed (Fig. 6). The
internalization of nanoparticles within cells could occur via
processes including phagocytosis, fluid-phase endocytosis, and
receptor-mediated endocytosis. The viability of both PC-3 and
MCF-7 cells post internalization of T-AuNP-1 suggests that the
phytochemical coating renders the nanoparticles to be non toxic
to cells. Such internalization of gold nanoparticles, keeping the
cellular machinery intact, will provide new opportunities for
probing cellular processes via nanoparticulate-mediated imaging.
Cytotoxicity studies
The cytotoxicity of T-AuNP-1 under in vitro conditions in
prostate (PC-3) and breast (MCF-7) cancer cells was examined in
terms of the effect of gold nanoparticles on cell proliferation by
the MTT assay. Untreated cells as well as cells treated with 10,
25, 50, 100, and 150 mM concentrations of gold nanoparticles for
24 h were subjected to the MTT assay for cell viability determi-
nation. In this assay, only cells that are viable after 24 h exposure
to the sample are capable of metabolizing a dye (3-(4,5-dime-
thylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) efficiently
and produce purple coloured crystals which are dissolved in
a detergent and analyzed sphectrophotometrically. After 24 h of
post treatment, PC-3 and MCF-7 cells showed excellent viability
even up to 150 mM concentrations of T-AuNP-1 (Fig. 7). These
results clearly demonstrate that the phytochemicals within tea
provide a non-toxic coating on gold nanoparticles and corrob-
orate the results as seen in the internalization studies discussed
above. It is also important to recognize that a vast majority of
gold (I) and gold (III) compounds exhibit varying degrees of
cytotoxicity to a variety of cells.104,105 The lack of any noticeable
toxicity of T-AuNP-1 provides new opportunities for the safe
delivery and applications of such nanoparticles in molecular
imaging and therapy.
Conclusions
The unique chemical, physical, photophysical, topological and
radiological properties rendered by nanoparticulate gold (and of
other metals/non metals) will continue to unravel a new knowl-
edge base to invent a plethora of new technologies and productsFig. 7 Dose dependent MTT cytotoxicity assay of T-AuNP-1 in MCF-7
breast cancer cells and PC-3 prostate cancer cells.
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for medical, civilian, defense, environmental and space explora-
tion applications. Over the next decade, advances in nano-
medicine will likely impact all of us. Although there is no
question of the scientific power and the positive impact of
nanoscience and nanotechnology in transforming medical diag-
nosis and therapy, the potential toxic side effects of nanoparticles
administered via intravenous or oral pathways cannot be dis-
counted. Therefore, concerted efforts must be invested in the
development of non-toxic nanoparticles for utility in a wide
spectrum of applications. The studies reported in this paper serve
as a unique example of the kinetic propensity of phytochemicals,
present in tea, to reduce gold metal at micro or picomolar/
sub-nanomolar concentrations to the corresponding gold nano-
particles. The versatile phytochemical-mediated green nano-
technological process has been shown to be effective in both the
generation and stabilization of non-toxic gold nanoparticles for
direct applications in a myriad of diagnostic and therapeutic
applications. Occlusion of cancer fighting phytochemicals in
various plant species and their future utility in the development
of tumor specific gold nanoparticles will provide unprecedented
opportunities toward the design and development of functional
gold nanoparticles that can be safely produced, stored and
shipped world wide.Acknowledgements
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